Evidence map›Paper›PMID 24416454›Full record

ArticlePloS one2014

Interaction of human laminin receptor with Sup35, the [PSI⁺] prion-forming protein from S. cerevisiae: a yeast model for studies of LamR interactions with amyloidogenic proteins.

Christine Pampeno, Irina L Derkatch, Daniel Meruelo

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Christine PampenoGene Therapy Center, Cancer Institute and Department of Pathology, New York University School of Medicine, New York, New York, United States of America.
Irina L DerkatchDepartment of Neuroscience, College of Physicians and Surgeons of Columbia University, New York, New York, United States of America.
Daniel MerueloGene Therapy Center, Cancer Institute and Department of Pathology, New York University School of Medicine, New York, New York, United States of America.
New York University · USColumbia University · US

Funding

Sindbis Vectors For Advanced Pancreatic Cancer TherapyR01CA100687 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MERUELO, DANIEL · 2004 to 2008
$1.5M
Investigation of the Establishment of the Prion StateR01GM070934 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DERKATCH, IRINA L · 2006 to 2010
$1.3M
NCI NIH HHS CA100687NCI NIH HHS R01 CA100687NIGMS NIH HHS 7R01 GM070934-06NIGMS NIH HHS R01 GM070934
6 · The paper itself

Abstract

The laminin receptor (LamR) is a cell surface receptor for extracellular matrix laminin, whereas the same protein within the cell interacts with ribosomes, nuclear proteins and cytoskeletal fibers. LamR has been shown to be a receptor for several bacteria and viruses. Furthermore, LamR interacts with both cellular and infectious forms of the prion protein, PrP(C) and PrP(Sc). Indeed, LamR is a receptor for PrP(C). Whether LamR interacts with PrP(Sc) exclusively in a capacity of the PrP receptor, or LamR specifically recognizes prion determinants of PrP(Sc), is unclear. In order to explore whether LamR has a propensity to interact with prions and amyloids, we examined LamR interaction with the yeast prion-forming protein, Sup35. Sup35 is a translation termination factor with no homology or functional relationship to PrP. Plasmids expressing LamR or LamR fused with the green fluorescent protein (GFP) were transformed into yeast strain variants differing by the presence or absence of the prion conformation of Sup35, respectively [PSI⁺] and [psi⁻]. Analyses by immunoprecipitation, centrifugal fractionation and fluorescent microscopy reveal interaction between LamR and Sup35 in [PSI⁺] strains. The presence of [PSI⁺] promotes LamR co-precipitation with Sup35 as well as LamR aggregation. In [PSI⁺] cells, LamR tagged with GFP or mCherry forms bright fluorescent aggregates that co-localize with visible [PSI⁺] foci. The yeast prion model will facilitate studying the interaction of LamR with amyloidogenic prions in a safe and easily manipulated system that may lead to a better understanding and treatment of amyloid diseases.

Indexed as

Models, BiologicalAmyloidogenic ProteinsCentrifugationFluorescent Antibody TechniqueGreen Fluorescent ProteinsHumansImmunoprecipitationPeptide Termination FactorsProtein BindingReceptors, LamininRecombinant Fusion ProteinsSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsAmyloidogenic ProteinsGreen Fluorescent ProteinsPeptide Termination FactorsReceptors, LamininRecombinant Fusion ProteinsSaccharomyces cerevisiae ProteinsSUP35 protein, S cerevisiae

Identifiers

PMID24416454
PMCPMC3885751
OpenAlexW2067441181

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.